OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Compan ...

Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]

Core Insights - Daxor Corporation is participating in the Maxim Growth Summit, a premier small-cap investor event featuring 40 promising healthcare companies [1][7] - The event will take place on October 22-23, 2025, at the Hard Rock Hotel in New York City, with Daxor's CEO Michael Feldschuh engaging with institutional investors [1][2] Company Overview - Daxor Corporation focuses on addressing the healthcare industry's challenge of accurately measuring blood volume, which is crucial for optimal patient care and reducing hospital stays [4] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [4] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning it for market expansion [4]

Core Insights - Daxor Corporation will showcase its next-generation Blood Volume Analysis (BVA) diagnostic system at the MedAxiom Cardiovascular Transforum Fall'25 Conference, which is a key event for cardiovascular organizational performance solutions [1][2] - The launch of the new BVA system is expected to enhance sales momentum and strengthen market leadership by addressing critical issues such as hospital readmissions and resource optimization [2] - Daxor is focused on solving the healthcare challenge of accurately measuring blood volume, which is crucial for improving patient care and reducing hospital stays, particularly for conditions like heart failure [3] Company Overview - Daxor Corporation is recognized as a leader in blood volume measurement technology, with a patented, FDA-cleared BVA diagnostic system that provides real-time, precise data [3] - The company has 50 years of experience in the industry and operates a state-of-the-art manufacturing facility in the U.S., which supports its market expansion efforts [3] - Daxor's technology aims to empower clinicians to make individualized treatment decisions, thereby improving patient outcomes and enhancing efficiencies in value-based healthcare [3]

Core Insights - Daxor Corporation's BVA technology significantly reduces hospital readmissions and improves survival rates in high-cost heart failure segments, validated by new clinical data presented at the HFSA Annual Scientific Meeting [1][3] - The newly FDA-cleared BVA analyzer is expected to capture a substantial share of the multi-billion-dollar market due to its enhanced ease of use, speed, and over 95% accuracy [2][3] Clinical Validation - Clinical findings indicate that patients optimally managed with BVA technology experienced zero unplanned readmissions, contrasting sharply with 57-77% for those with imbalances in blood volume [7] - The use of BVA-guided care in LVAD implantation resulted in improved outcomes, increasing 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%, while reducing 30-day readmissions from 28.6% to 18.5% [7] - Patients with Cardiac Amyloidosis showed significantly higher total blood and plasma volumes, indicating the diagnostic potential of BVA for accurate treatment [7] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [4] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning it for accelerated market expansion [4]

Core Insights - Daxor Corporation is set to present its newly FDA-cleared blood volume analyzer (BVA) at the HFSA Annual Scientific Meeting, marking a significant advancement in fluid management technology for heart failure treatment [1][2] - The new BVA system is designed to enhance clinical potential and market leadership, being three times faster than its predecessor and requiring 50% less blood for testing while maintaining over 95% accuracy [2][3] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [5] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning itself for accelerated market expansion [5] Market Impact - The introduction of the new BVA system is expected to drive significant improvements in patient outcomes and economic value in the heart failure sector, potentially transforming fluid management practices [3][5] - Daxor's participation in the HFSA meeting highlights its commitment to advancing heart failure science and improving patient management through innovative technology [2][3]

Core Insights - The study published in the Journal of Critical Care reveals frequent inaccuracies in clinical assessments of fluid status in critically ill patients, particularly those with sepsis and COVID-19 [1][2] - Daxor Corporation's BVA technology is highlighted as a solution to improve fluid management in critical care settings, emphasizing the need for accurate blood volume measurement [4][5] Study Findings - A significant percentage of patients were misclassified during clinical assessments, with 48% of COVID-19 patients incorrectly deemed hypervolemic when they were actually hypovolemic [8] - The study indicates that the albumin transudation rate (ATR) was persistently elevated in both sepsis and COVID-19 patients, suggesting ongoing capillary leakage [8] - Sepsis patients exhibited a higher ATR compared to COVID-19 patients, indicating more severe endothelial dysfunction despite lower admission severity scores [8] Company Positioning - Daxor's FDA-approved BVA-100™ Analyzer was utilized in the study, showcasing its capability to provide objective measurements of total blood volume and ATR [4] - The company has received FDA clearance for a new rapid BVA system, which is three times faster than the BVA-100™ and maintains over 95% accuracy, addressing urgent diagnostic needs in critical care [5][6] - Daxor is positioned for revenue expansion in critical care medicine, supported by new data, funding opportunities, and advancements in its technology [6][9]

Core Insights - Daxor Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET [1] Company Overview - Daxor Corporation is addressing a significant issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [3] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor has 50 years of experience in the field and operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning it for market expansion [3] Investor Engagement - Investors interested in the presentation can register for the conference through a provided link [2] - CEO Michael Feldschuh will be available for one-on-one meetings with registered investors at the conference [2] - For further inquiries, investors can contact Bret Shapiro at CORE IR via phone or email [2][6]

Core Insights - Daxor Corporation has achieved significant milestones in 2025, including FDA clearance for a new rapid Blood Volume Analysis (BVA) system, marking a transformative moment for the company [4][8] - The company reported a 73% increase in unaudited revenues for the first half of 2025 compared to the same period in 2024, driven by sales of diagnostic kits and military contracts [6][8] - Daxor's net asset value increased to $36.6 million as of June 30, 2025, reflecting a $3.97 million increase from the previous year [6][8] Product Innovation - The new BVA system is three times faster, portable, and smaller than the existing BVA-100, while maintaining the ability to measure total blood volume, red blood cell volume, plasma volume, and albumin transudation rate [4][8] - The company is committed to rolling out the new BVA system and accelerating commercial operations alongside ongoing research and development for additional products [8] Financial Performance - Daxor's operating division reported a significant revenue increase, with net asset value per share rising to $7.15, up $0.40 from the previous year [6][8] - The company experienced a net decrease in unrealized appreciation on investments but reported net realized gains of $468,212 for the first half of 2025 [6] Market Adoption and Clinical Validation - The adoption of Daxor's BVA technology has accelerated, with new accounts contributing to revenue growth and clinical acceptance [6][8] - A significant study published in the American Heart Journal highlighted the utility of BVA technology in managing heart failure, showing that patients identified as euvolemic had 2.61 times better survival rates [9] Industry Engagement - Daxor actively engaged with the medical community through industry events to showcase its technology and foster awareness among cardiovascular professionals [7][9] - The company exhibited at major conferences, further solidifying its presence in the healthcare sector [9]

Core Insights - Daxor Corporation has achieved FDA 510(k) clearance for its next-generation, rapid, compact, hand-held Blood Volume Analyzer (BVA), marking a significant milestone for the company [1] - The Nasdaq Closing Bell Ceremony held on August 8, 2025, celebrated this achievement and is now available for replay [2] Company Overview - Daxor Corporation is addressing a critical issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays for conditions like heart failure [3] - The company has over 50 years of experience in innovation and offers a patented, FDA-cleared Blood Volume Analysis diagnostic that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning itself for market expansion [3]